Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults

Summary

After consolidation therapy adult patients (≥18 yr) with Ph-negative ALL will be treated with continuation chemotherapy or allogeneic hematopoietic stem cell transplantation (alloHSCT) according to both measurable residual disease (MRD) and results of genetic study performed at baseline.

Timeline

Start

2019-11-25

Primary completion

2026-11

Completion

2027-02

Publications

• Ribera JM, Torrent A, Morgades M, Barrena S, Ribera J, Genesca E, Gonzalez-Campos J, Martinez-Cibrian N, Montesinos P, Hernandez Sanchez A, Barba P, Zapico E Sr, Sanchez R, Novo A, Sitges M, Maluquer Artigal C, Such E, Botella C, Queipo de Llano MP, Cabrero M, Vicent A, Lopez de Ugarriza P, Tormo M, Gonzalez-Gonzalez BJ, Garcia-Cadenas I, Rodriguez-Medina C, Martinez Sanchez P, Bermudez A, Gomez-Centurion I, Herrero-Garcia M, Ciudad J, Navas-Acosta J, Hermosin L, Serrano J, Raposo-Puglia JA, Solan L, Roldan-Galiacho V, de Laiglesia A, Gomez-Perez L, Sole-Rodriguez M, Casado MS Sr, Llorente Gonzalez L, Barrios Decoud D, Vall-Llovera F, Algarra JL, Amador L, Garcia-Boyero R, Cladera A, Bergua Burgues JM, Calasanz MJJ, Granada I, Feliu E, Hernandez-Rivas JM, Orfao A. Genetics and MRD for therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Blood. 2026 May 4:blood.2025032645. doi: 10.1182/blood.2025032645. Online ahead of print.

Drugs

Indications